ECRM presents awards to three suppliers
ORLANDO, Fla. — ECRM on Wednesday evening announced the Vendor Award recipients for its ECRM Cough & Cold and Allergy event held here, recognizing GOJO Industries for the “Most Prepared,” the Emerson Group for “Best Room” and Cobalis for “Best New Product.”
The awards, sponsored by The Drug Store News Group, represent a tally of retail buyer votes on each of the categories.
GOJO Industries is preparing to relaunch its Purell hand sanitizer business after acquiring that brand back from Johnson & Johnson last year. Under the direction of sales VP Tim Cleary, GOJO’s team of seven sales representatives showcased for buyers the Purell brand heritage and how the company plans to better position the brand in the coming months and years.
The Emerson Group showcased its host of client companies, including Similasan, Fleming Pharmaceuticals and Dynova Labs, among others, in a grand ballroom sporting a "winter wonderland" theme.
Cobalis was recognized for its introduction of PreHistin, a supplement ideal for allergy sufferers as it helps regulate the function of histamines. The new product is available as a quick-dissolve cherry lozenge.
Dulcolax, CCA encourage consumers to get screened for colon cancer
RIDGEFIELD, Conn. — Dulcolax has teamed up with the Colon Cancer Alliance and American fashion designer Carmen Marc Valvo to encourage men and women to be proactive about their colon health by getting a colonoscopy.
According to a new survey conducted on behalf of Boehringer Ingelheim, the makers of Dulcolax, and the CCA, more than a quarter (27%) of respondents ages 50 years and older have not had a colonoscopy, a colon cancer screening test, with the most often-cited reason being that they do not have a family history of colon cancer. What’s more, 60% of those respondents said they would be more concerned about the preparation than the actual procedure. Valvo, who was diagnosed with colon cancer eight years ago, said the benefits of a colon cancer screening outweighed the discomfort.
"I certainly understand why people are hesitant to be examined, but the fact is, it’s not nearly as uncomfortable as you might imagine, and any discomfort from the screening is surely outweighed by the benefits of preventing cancer from developing or catching it in its early stages," Valvo said. Valvo now is cancer-free.
As part of its support of colon cancer screenings, Boehringer Ingelheim noted that a portion of proceeds from the purchase of Dulcolax supports free colon cancer screenings for those in need.
FDA targets unapproved cough-cold, allergy drugs with Unapproved Drugs Initiative
SILVER SPRING, Md. — The Food and Drug Administration has taken action against makers of prescription drugs for cough-cold and allergies that don’t have regulatory approval, the agency said Wednesday.
The action is part of the agency’s Unapproved Drugs Initiative, which seeks to remove from the market drugs that have not received approval. In many cases, the drugs were marketed before the FDA adopted its current regulatory standards.
The products include a wide range of drugs with active ingredients ranging from guaifenesin to dextromethorphan to pseudoephedrine hydrochloride, which also appear in a number of FDA-approved prescription and over-the-counter products. The agency said that many healthcare providers didn’t know the drugs didn’t have FDA approval because they lacked any labels indicating they didn’t.
“Removing these unapproved products from the market will reduce potential risks to consumers,” FDA Office of Compliance director Deborah Autor said. “There are many FDA-approved prescription products, as well as appropriately marketed over-the-counter products, available to treat cough-cold and allergy symptoms; so we expect little or no negative impact on consumers from the removal of these unapproved products.”